Tag: AFFiRiS

AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease
June 3, 2020 Off

AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease

By Dino Mustafić

AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), said Wednesday that detailed preclinical results with its monoclonal antibody mAB C6-17 to treat Huntington’s Disease (HD) were published in the peer-reviewed journal Neurobiology of Disease.

Affiris to proceed with P2study with lead treatment for Parkinson’s
January 27, 2020 Off

Affiris to proceed with P2study with lead treatment for Parkinson’s

By Dino Mustafić

AFFiRiS AG, a clinical-stage biopharmaceutical company developing novel disease-modifying specific active immunotherapies (SAITs) for patients with neurodegenerative diseases, will proceed with the preparations for the planned phase 2 study and confirms its intended initiation in the US and Europe in the second half of 2020.